Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
518339
Reference Type
Journal Article
Title
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions
Author(s)
Savoia, C; Schiffrin, EL
Year
2007
Is Peer Reviewed?
Yes
Journal
Clinical Science
ISSN:
0143-5221
EISSN:
1470-8736
Volume
112
Issue
7-8
Page Numbers
375-384
Language
English
DOI
10.1042/cs20060247
Abstract
More than 80% of patients with Type 2 diabetes mellitus develop hypertension, and approx. 20% of patients with hypertension develop diabetes. This combination of cardiovascular risk factors will account for a large proportion of cardiovascular morbidity and mortality. Lowering elevated blood pressure in diabetic hypertensive individuals decreases cardiovascular events. In patients with hypertension and diabetes, the pathophysiology of cardiovascular disease is multifactorial, but recent evidence points toward the presence of an important component dependent on a low-grade inflammatory process. Angiotensin II may be to a large degree responsible for triggering vascular inflammation by inducing oxidative stress, resulting in up-regulation of pro-inflammatory transcription factors such as NF-kappa B (nuclear factor kappa B). These, in turn, regulate the generation of inflammatory mediators that lead to endothelial dysfunction and vascular injury. Inflammatory markers (e.g. C-reactive protein, chemokines and adhesion molecules) are increased in patients with hypertension and metabolic disorders, and predict the development of cardiovascular disease. Lifestyle modification and pharmacological approaches (such as drugs that target the renin-angiotensin system) may reduce blood pressure and inflammation in patients with hypertension and metabolic disorders, which will reduce cardiovascular risk, development of diabetes and cardiovascular morbidity and mortality.
Keywords
adhesion molecule; blood pressure; cardiovascular risk factor; cytokine; diabetes; hypertension; inflammation; c-reactive protein; coronary-artery-disease; smooth-muscle-cells; monocyte chemoattractant protein-1; apparently healthy-men; intercellular-adhesion molecule-1; cardiovascular risk-factors; kappa-b; activation; future myocardial-infarction; urinary albumin excretion
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity